540779-19-9

Upstream product

• 860778-52-5 (E)-ethyl 3-(4-bromo-3-nitrophenyl)acrylate 
• 163596-75-6 4-bromo-3-nitrobenzaldehyde 
• 1352042-73-9 ethyl (E)-4-[3-(1-adamantyl)-4-benzyloxyphenyl]-3-aminocinnamate 
• 1352042-59-1 ethyl (E)-4-[3-(1-adamantyl)-4-benzyloxyphenyl]-3-nitrocinnamate 
• 540779-18-8 ethyl (E)-3-bromo-4-(trifluoromethanesulfonyloxy)cinnamate 
• 221137-01-5 3-(1-adamantyl)-4-benzyloxyphenylboronic acid 

Downstream Products

• 540779-20-2 ethyl (E)-4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-bromocinnamate 
• 540779-16-6 (E)-4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-bromocinnamic acid 

Relevant academic research and scientific papers

Analogues of orphan nuclear receptor small heterodimer partner ligand and apoptosis inducer (E)-4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid. 2. Impact of 3-chloro group replacement on inhibition of proliferation and induction of apoptosis of

The parent phenol of adapalene and its (E)-cinnamic acid analogue were found to induce cancer cell apoptosis but cause adverse systemic effects when administered to mice. In contrast, their respective 5-Cl- and 3-Cl-substituted analogues had their adverse

Induction of apoptosis in cancer cells

The present invention provides compounds that are inducers or inhibitors of apoptosis or apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.